Company Filing History:
Years Active: 2025
Title: Innovations by Jean-Christophe Vanherck
Introduction
Jean-Christophe Vanherck is a notable inventor based in Leuven, Belgium. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds for treating specific disorders. With a total of 2 patents, his work focuses on innovative solutions for health-related challenges.
Latest Patents
Jean-Christophe Vanherck's latest patents include the invention of heterocycle derivatives for treating TRPM3 mediated disorders. This invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, specifically targeting conditions such as pain and inflammatory hypersensitivity. The invention also encompasses a method for the prevention or treatment of these disorders, showcasing his commitment to advancing medical science.
Career Highlights
He is affiliated with Katholieke Universiteit Leuven, where he engages in research and development activities. His work at the university allows him to collaborate with other experts in the field, further enhancing the impact of his inventions.
Collaborations
One of his notable collaborators is Patrick Chaltin, with whom he has worked on various projects aimed at improving therapeutic options for patients.
Conclusion
Jean-Christophe Vanherck's contributions to the field of medicinal chemistry through his patents and collaborations highlight his dedication to innovation in healthcare. His work continues to pave the way for new treatments that can significantly improve patient outcomes.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.